Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Niren Murthy
University of California Berkeley, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
GenEdit
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Conflict of Interest Committee determined that the PI’s interest in GenEdit, is related to the interest of the project and represents an FCOI in that those interests could directly and significantly affect the design, conduct or reporting of the PHS-funded research because technology used in experiments in the project could potentially increase the value of the IP of that technology, which the company is interested in licensing.
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold Nanoparticles
Project Narrative The central objective of this collaborative proposal is to develop a new delivery vehicle for CRISPR/Cas9 based therapeutics, termed CRISPR-Gold, which is composed of gold nanoparticles complexed with Cas9 RNP, donor DNA and the endosomal disruptive polymer PASp(DET). The experiments in this proposal focus on using CRISPR-Gold to treat Duchenne muscular dystrophy (DMD), which is a fatal disease caused by mutations in the dystrophin gene. If successful, the experiments in this proposal have the potential to have a transformative effect on the treatment of DMD, given CRISPR-Gold?s unique ability to correct the dystrophin gene in vivo.
Filed on September 07, 2017.
Tell us what you know about Niren Murthy's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Niren Murthy filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Niren Murthy | Emory University | Conflict of Interest | Microbial Medical | Value cannot be readily determined |
| Niren Murthy | University of California Berkeley | Conflict of Interest | Microbial Medical | Value cannot be readily determined |
Other search results for: “Niren Murthy”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Niren Murthy | University of California Berkeley | Financial Disclosure | Microbial Medical | |
| Niren Murthy | University of California Berkeley | Financial Disclosure | Microbial Medical | |
| Niren Murthy | University of California Berkeley | Financial Disclosure | GenEdit | |
| Niren Murthy | University of California Berkeley | Financial Disclosure | Microbial Medical, Inc. |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.